Accessibility Menu
BioRestorative Therapies logo

BioRestorative Therapies(NASDAQ) BRTX

Market Cap$6.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-100%
5 Year-99%
1 Year-83%
1 Month-28%
$0.25
-6.98%
-0.02Today
BioRestorative Therapies last closing stock price
MetricPriceDate
Last closeUSD 0.272026-07-28
BioRestorative Therapies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-17.33%USD 0.322026-07-21
1 month-27.87%USD 0.372026-06-26
3 month+32.18%USD 0.202026-04-29
Year to date-77.31%USD 1.182025-12-31
1 year-83.02%USD 1.572025-07-28
3 year-90.65%USD 2.852023-07-28
5 year-98.61%USD 19.202021-07-29
Since inception-100%USD 112,000.002009-04-20

BioRestorative Therapies Financials at a Glance

Market Cap

$6.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$357.87K

Net Income (TTM)

-$11.06M

EPS (TTM)

-$1.12

P/E Ratio

-0.24

Dividend

$0.00

Beta (Volatility)

1.12 (Average)

Price

$0.25

Volume

764,760

Open

$0.26

Previous Close

$0.25

Daily Range

$0.23 - $0.28

52-Week Range

$0.16 - $1.89

Estimated Earnings Date

Aug 11, 2026

BRTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioRestorative Therapies

BioRestorative Therapies develops cell-based treatments for back pain and metabolic disorders. Its therapies aim to help people with chronic spine issues or obesity. The company also sells cosmetic products using cell-derived ingredients.

What’s in the BioRestorative Toolbox?

  • Disc/Spine Therapy (BRTX-100): Cell-based treatment for chronic lower back pain; 16.6% of 2025 revenue; targets patients with degenerative disc disease.
  • Metabolic Program (ThermoStem): Preclinical therapy using brown fat stem cells for obesity and diabetes; not yet generating revenue.
  • BioCosmeceuticals: Cell-derived cosmetic serum; 83.4% of 2025 revenue; sold to spas and distributors.
  • Curved Needle Device: Investigational tool for delivering therapies to the spine; not yet commercialized.

Growth and Expansion: The BioRestorative Adventure

  • Partnered with Rohto Pharmaceutical, Pfizer, and University of Pennsylvania for research collaborations (2025).
  • Expanded cGMP manufacturing facility and secured New York State licenses for tissue processing (2025).
  • Launched new executive hires for commercialization and global operations (2025).
  • Received FDA Fast Track for BRTX-100 and completed Phase 2 trial enrollment (2025-2026).
  • Issued new patents for ThermoStem in Europe, Israel, and Japan, and received a notice of allowance for a patent in Australia (2025).

What Makes BioRestorative Stand Out?

The company holds exclusive patents for its cell therapies and manufacturing processes. It operates its own clinical-grade cell production facility. Strategic partnerships with major pharmaceutical and academic groups support its research pipeline.

Five Things You Need to Know

  • 2025 revenue was $359,700, down 10.3% from 2024.
  • Cosmetic products made up 83.4% of 2025 revenue.
  • Net loss widened to $14.2 million in 2025, up 58% from 2024.
  • All sales came from just two customers in 2025.
  • Auditor issued a going concern warning due to cash shortfall in 2025.

Bottom Line

BioRestorative has shifted from research to early commercialization, focusing on cell therapies and cosmetic products. The company faces financial challenges but continues to invest in clinical trials and partnerships.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Lance Alstodt

Website

www.biorestorative.com

Headquarters

Melville, NY 11747, US

BRTX Financials

Key Financial Metrics (TTM)

Gross Margin

92.09%

Operating Margin

-3975.00%

Net Income Margin

-3089.55%

Return on Equity

-423.84%

Return on Capital

-4386.10%

Return on Assets

-238.27%

Earnings Yield

-4.17%

Dividend Yield

0.00%

Payout Ratio

-0.05%

Stock Overview

Market Cap

$6.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

25.48M

Volume

764.76K

Avg. Volume

10.31M

Financials (TTM)

Gross Profit

$329.55K

Operating Income

-$14.23M

EBITDA

-$10.85M

Operating Cash Flow

-$11.82M

Capital Expenditure

-$79.68K

Free Cash Flow

-$11.90M

Cash & ST Invst.

$3.59M

Total Debt

$34.52K

BioRestorative Therapies Performance Analysis

BioRestorative Therapies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 119,800160.4%
20232023-12-31USD 145,80021.7%
20242024-12-31USD 401,000175.0%
20252025-12-31USD 359,700-10.3%
BioRestorative Therapies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-301113.2%
Q32025-09-30-96.1%
Q42025-12-3166.1%
Q12026-03-3118.2%
BioRestorative Therapies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.65-90.2%
20232023-12-31USD -2.47-32.4%
20242024-12-31USD -1.16-53.2%
20252025-12-31USD -1.5836.9%
BioRestorative Therapies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3053.1%
Q32025-09-30-10.0%
Q42025-12-31-9.1%
Q12026-03-3133.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$23.17K

-7.3%

Gross Profit

$15.79K

-28.5%

Gross Margin

68.13%

N/A

Market Cap

$6.79MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$485.18K

N/A

Employees

14

N/A

Net Income

-$2.15M

+59.7%

EBITDA

-$2.10M

+60.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.59M

-60.6%

Total Debt

$34.52K

N/A

Accounts Receivable

$13.30K

-46.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$34.52K

N/A

Return on Assets

-2.38%

N/A

Return on Invested Capital

-4.70%

N/A

Free Cash Flow

-$3.81M

-35.3%

Operating Cash Flow

-$3.81M

-37.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IMRNImmuron Limited
$1.10-1.35%
BOLTBolt Biotherapeutics, Inc.
$3.85-3.96%
TRAWTraws Pharma, Inc.
$0.48-6.10%
EVGNEvogene Ltd.
$0.48-2.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$8.41-0.06%
TAT&T
$23.94-0.03%
SMRNuScale Power
$7.59-0.08%
ORCLOracle
$117.74-0.02%

Questions About BRTX

What is the current price of BioRestorative Therapies?

BioRestorative Therapies is trading at $0.25 per share.

What is the 52-week range for BioRestorative Therapies?

Over the past 52 weeks, BioRestorative Therapies has traded between $0.16 and $1.89.

How much debt does BioRestorative Therapies have?

As of the most recent reporting period, BioRestorative Therapies reported total debt of $34.52K.

How much cash does BioRestorative Therapies have on hand?

BioRestorative Therapies reported $3.11M in cash and cash equivalents in its most recent financial results.

What is BioRestorative Therapies’s dividend yield?

BioRestorative Therapies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services